For questions about BMS medicines during this time
please call 1-800-721-8909.

ONUREG® is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

Asset 2

NOW APPROVED

THE FIRST AND ONLY
FDA-approved continued AML treatment for patients in first remission1,2

ONUREG® is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

Arrow

Full Prescribing Information

Arrow

How to order and access ONUREG®

Arrow

Approval announcement letter

  • Register to receive updates about ONUREG®

    *Required field

Bristol-Myers Squibb Company values your privacy. Bristol-Myers Squibb Company, its affiliates, and its agents will not sell or rent your personal information. By providing your information, you acknowledge that you have read and agree to Bristol-Myers Squibb Company's Privacy Policy.

Medical Inquiries and Reporting

Submit an online request form or call 1-888-771-0141.